Thus, the targeted degradation of STING by tumor cells “undoes”, at least in part, the efforts of cisplatin-induced cGAS activation, leading to incomplete activation of cGAS-STING in the direction of immunosuppressive TME, which ultimately requires additional STING agonists to achieve the desired therapeutic effect. This evidence concerns the gene STING1 and neoplasm.